Jamjoom Pharma H1 2024 net profit rises to SAR 209.9M; Q2 at SAR 106.7M

06/08/2024 Argaam Exclusive

View other reports

Jamjoom Pharmaceuticals Factory Co. (Jamjoom Pharma) reported a net profit of SAR 209.9 million in H1 2024, an increase of 23% from SAR 170.7 million in the year-earlier period.

Financials (M)

Item	6m 2023	6m 2024	Change‬
Revenues	599.25	731.20	22.0 %
Gross Income	397.70	467.59	17.6 %
Operating Income	186.47	230.84	23.8 %
Net Income	170.67	209.92	23.0 %
Average Shares	70.00	70.00	-
EPS (Riyals)	2.44	3.00	23.0 %

The company cited higher revenue, offset by cost of sales, but was further improved through cost efficiencies in other operating expenses, and other income.

Current Quarter Comparison (M)

Compared With The

Item	Q2 2023	Q2 2024	Change‬
Revenues	298.40	345.74	15.9 %
Gross Income	198.10	218.18	10.1 %
Operating Income	92.56	104.26	12.6 %
Net Income	86.27	106.95	24.0 %
Average Shares	70.00	70.00	-
EPS (Riyals)	1.23	1.53	24.0 %

Item	Q1 2024	Q2 2024	Change‬
Revenues	385.46	345.74	(10.3 %)
Gross Income	249.40	218.18	(12.5 %)
Operating Income	126.58	104.26	(17.6 %)
Net Income	102.97	106.95	3.9 %
Average Shares	70.00	70.00	-
EPS (Riyals)	1.47	1.53	3.9 %

Q2 2024 net profit reached SAR 107 million, up 24% from SAR 86.2 million in the year-earlier period, spurred by revenue growth, improved cost management and efficiency, as well as other income.

On a quarterly basis, Q2 2024 net earnings grew 3.9% from SAR 102.9 million in Q1 2024.

Total shareholders’ equity (no minority interest) reached SAR 1.46 billion by June 30, 2024, compared to SAR 1.35 billion in the corresponding period of the year before.

View More Financial Results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	-	-	-	-	-	-
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	-	-	-	-	-	-
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	-	-	-	-	-	-
Q1 2018	-	-	-	-	-	-
Q2 2018	-	-	-	-	-	-
Q3 2018	-	-	-	-	-	-
Q4 2018	-	-	-	-	-	-
2018	701.30	-	442.77	-	171.70	-
Q1 2019	-	-	-	-	-	-
Q2 2019	-	-	-	-	-	-
Q3 2019	-	-	-	-	-	-
Q4 2019	-	-	-	-	-	-
2019	731.73	4.3 %	422.37	(4.6 %)	174.54	1.7 %
Q1 2020	-	-	-	-	-	-
Q2 2020	-	-	-	-	-	-
Q3 2020	-	-	-	-	-	-
Q4 2020	-	-	-	-	-	-
2020	805.31	10.1 %	513.30	21.5 %	229.49	31.5 %
Q1 2021	121.82	-	77.37	-	14.74	-
Q2 2021	193.05	-	124.75	-	49.73	-
Q3 2021	-	-	-	-	-	-
Q4 2021	-	-	-	-	-	-
2021	735.68	(8.6 %)	474.69	(7.5 %)	184.77	(19.5 %)
Q1 2022	243.78	100.1 %	164.32	112.4 %	77.42	425.2 %
Q2 2022	238.30	23.4 %	153.06	22.7 %	57.61	15.9 %
Q3 2022	237.76	-	151.13	-	60.03	-
Q4 2022	196.84	-	125.41	-	38.26	-
2022	916.67	24.6 %	593.92	25.1 %	233.33	26.3 %
Q1 2023	300.85	23.4 %	199.61	21.5 %	93.91	21.3 %
Q2 2023	298.40	25.2 %	198.10	29.4 %	92.56	60.7 %
Q3 2023	292.61	23.1 %	187.23	23.9 %	84.67	41.1 %
Q4 2023	207.86	5.6 %	118.86	(5.2 %)	42.24	10.4 %
2023	1,100.82	20.1 %	703.79	18.5 %	313.38	34.3 %
Q1 2024	385.46	28.1 %	249.40	24.9 %	126.58	34.8 %
Q2 2024	345.74	15.9 %	218.18	10.1 %	104.26	12.6 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2014	-	-	-	-	-	-
2015	-	-	-	-	-	-
2016	-	-	-	-	-	-
2017	-	-	-	-	-	-
2018	701.30	-	442.77	-	171.70	-
2019	731.73	4.3 %	422.37	(4.6 %)	174.54	1.7 %
2020	805.31	10.1 %	513.30	21.5 %	229.49	31.5 %
2021	735.68	(8.6 %)	474.69	(7.5 %)	184.77	(19.5 %)
2022	916.67	24.6 %	593.92	25.1 %	233.33	26.3 %
2023	1,100.82	20.1 %	703.79	18.5 %	313.38	34.3 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2015	-	-	-	-	-	-
Q2 2015	-	-	-	-	-	-
Q3 2015	-	-	-	-	-	-
Q4 2015	-	-	-	-	-	-
2015	-	-	-	-	-	-
Q1 2016	-	-	-	-	-	-
Q2 2016	-	-	-	-	-	-
Q3 2016	-	-	-	-	-	-
Q4 2016	-	-	-	-	-	-
2016	-	-	-	-	-	-
Q1 2017	-	-	-	-	-	-
Q2 2017	-	-	-	-	-	-
Q3 2017	-	-	-	-	-	-
Q4 2017	-	-	-	-	-	-
2017	-	-	-	-	-	-
Q1 2018	-	-	-	-	-	-
Q2 2018	-	-	-	-	-	-
Q3 2018	-	-	-	-	-	-
Q4 2018	-	-	-	-	-	-
2018	150.84	-	2.15	-	150.84	2.15
Q1 2019	-	-	-	-	-	-
Q2 2019	-	-	-	-	-	-
Q3 2019	-	-	-	-	-	-
Q4 2019	-	-	-	-	-	-
2019	159.93	6.0 %	2.28	-	159.93	2.28
Q1 2020	-	-	-	-	-	-
Q2 2020	-	-	-	-	-	-
Q3 2020	-	-	-	-	-	-
Q4 2020	-	-	-	-	-	-
2020	206.86	29.3 %	2.96	-	206.86	2.96
Q1 2021	10.98	-	0.16	-	10.98	0.16
Q2 2021	41.19	-	0.59	-	41.19	0.59
Q3 2021	-	-	-	-	-	-
Q4 2021	-	-	-	-	-	-
2021	170.70	(17.5 %)	2.44	-	170.70	2.44
Q1 2022	43.53	296.3 %	0.62	(28.75)	72.28	1.03
Q2 2022	50.42	22.4 %	0.72	(4.27)	54.69	0.78
Q3 2022	45.60	-	0.65	(7.96)	53.56	0.77
Q4 2022	31.76	-	0.45	(6.98)	38.73	0.55
2022	171.31	0.4 %	2.45	(47.95)	219.26	3.13
Q1 2023	84.40	93.9 %	1.21	-	84.40	1.21
Q2 2023	86.27	71.1 %	1.23	-	86.27	1.23
Q3 2023	77.25	69.4 %	1.10	-	77.25	1.10
Q4 2023	44.48	40.1 %	0.64	-	44.48	0.64
2023	292.40	70.7 %	4.18	-	292.40	4.18
Q1 2024	102.97	22.0 %	1.47	-	102.97	1.47
Q2 2024	106.95	24.0 %	1.53	-	106.95	1.53

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2014	-	-	-	-	-	-
2015	-	-	-	-	-	-
2016	-	-	-	-	-	-
2017	-	-	-	-	-	-
2018	150.84	-	2.15	-	150.84	2.15
2019	159.93	6.0 %	2.28	-	159.93	2.28
2020	206.86	29.3 %	2.96	-	206.86	2.96
2021	170.70	(17.5 %)	2.44	-	170.70	2.44
2022	171.31	0.4 %	2.45	(47.95)	219.26	3.13
2023	292.40	70.7 %	4.18	-	292.40	4.18

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
2018	63.14 %	30.54 %	21.51 %
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
2019	57.72 %	29.63 %	21.86 %
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	-	-	-
2020	63.74 %	33.74 %	25.69 %
Q1 2021	-	-	-
Q2 2021	-	-	-
Q3 2021	-	-	-
Q4 2021	-	-	-
2021	64.52 %	28.43 %	23.20 %
Q1 2022	-	-	-
Q2 2022	-	-	-
Q3 2022	-	-	-
Q4 2022	64.79 %	28.15 %	23.92 %
2022	64.79 %	28.15 %	23.92 %
Q1 2023	64.62 %	28.21 %	23.76 %
Q2 2023	65.22 %	29.98 %	25.44 %
Q3 2023	65.25 %	30.78 %	26.33 %
Q4 2023	64.00 %	30.92 %	26.59 %
2023	63.93 %	30.89 %	26.56 %
Q1 2024	63.63 %	31.58 %	26.26 %
Q2 2024	62.82 %	31.59 %	26.93 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2014	-	-	-
2015	-	-	-
2016	-	-	-
2017	-	-	-
2018	63.14 %	30.54 %	21.51 %
2019	57.72 %	29.63 %	21.86 %
2020	63.74 %	33.74 %	25.69 %
2021	64.52 %	28.43 %	23.20 %
2022	64.79 %	28.15 %	23.92 %
2023	63.93 %	30.89 %	26.56 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	-	-	-
Q1 2021	63.51 %	-	9.02 %
Q2 2021	64.62 %	32.15 %	21.34 %
Q3 2021	-	-	-
Q4 2021	-	-	-
Q1 2022	67.40 %	34.26 %	29.65 %
Q2 2022	64.23 %	26.75 %	22.95 %
Q3 2022	63.56 %	27.86 %	22.53 %
Q4 2022	63.71 %	22.63 %	19.68 %
Q1 2023	66.35 %	33.30 %	28.05 %
Q2 2023	66.39 %	33.17 %	28.91 %
Q3 2023	63.98 %	31.24 %	26.40 %
Q4 2023	57.18 %	23.79 %	21.40 %
Q1 2024	64.70 %	34.80 %	26.71 %
Q2 2024	63.11 %	32.98 %	30.93 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2015	-	-	-	-
Q2 2015	-	-	-	-
Q3 2015	-	-	-	-
Q4 2015	-	-	-	-
Q1 2016	-	-	-	-
Q2 2016	-	-	-	-
Q3 2016	-	-	-	-
Q4 2016	-	-	-	-
Q1 2017	-	-	-	-
Q2 2017	-	-	-	-
Q3 2017	-	-	-	-
Q4 2017	-	-	-	-
Q1 2018	-	-	-	-
Q2 2018	-	-	-	-
Q3 2018	-	-	-	-
Q4 2018	-	-	-	-
Q1 2019	-	-	-	-
Q2 2019	-	-	-	-
Q3 2019	-	-	-	-
Q4 2019	-	-	-	-
Q1 2020	-	-	-	-
Q2 2020	-	-	-	-
Q3 2020	-	-	-	-
Q4 2020	-	-	-	-
Q1 2021	70.00	-	-	-
Q2 2021	70.00	-	-	16.98
Q3 2021	-	-	-	-
Q4 2021	-	-	-	-
Q1 2022	70.00	-	-	17.67
Q2 2022	70.00	-	-	18.03
Q3 2022	70.00	-	-	18.34
Q4 2022	70.00	2.45	3.13	17.38
Q1 2023	70.00	3.03	3.31	18.13
Q2 2023	70.00	3.54	3.76	19.36
Q3 2023	70.00	4.00	4.09	19.45
Q4 2023	70.00	4.18	4.18	20.06
Q1 2024	70.00	4.44	4.44	20.88
Q2 2024	70.00	4.74	4.74	20.90

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2014	-	-	-	-
2015	-	-	-	-
2016	-	-	-	-
2017	-	-	-	-
2018	70.00	2.15	2.15	14.28
2019	70.00	2.28	2.28	15.28
2020	70.00	2.96	2.96	16.84
2021	70.00	2.44	2.44	17.59
2022	70.00	2.45	3.13	17.38
2023	70.00	4.18	4.18	20.06

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2015	-	-	-
Q2 2015	-	-	-
Q3 2015	-	-	-
Q4 2015	-	-	-
Q1 2016	-	-	-
Q2 2016	-	-	-
Q3 2016	-	-	-
Q4 2016	-	-	-
Q1 2017	-	-	-
Q2 2017	-	-	-
Q3 2017	-	-	-
Q4 2017	-	-	-
Q1 2018	-	-	-
Q2 2018	-	-	-
Q3 2018	-	-	-
Q4 2018	-	-	-
Q1 2019	-	-	-
Q2 2019	-	-	-
Q3 2019	-	-	-
Q4 2019	-	-	-
Q1 2020	-	-	-
Q2 2020	-	-	-
Q3 2020	-	-	-
Q4 2020	-	-	-
Q1 2021	-	-	-
Q2 2021	-	-	-
Q3 2021	-	-	-
Q4 2021	-	-	-
Q1 2022	-	-	-
Q2 2022	-	-	-
Q3 2022	-	-	-
Q4 2022	-	-	-
Q1 2023	-	-	-
Q2 2023	25.26	23.82	4.62
Q3 2023	28.98	28.28	5.95
Q4 2023	27.53	27.53	5.73
Q1 2024	28.59	28.59	6.08
Q2 2024	30.69	30.69	6.96

Period	P/E	Adjusted P/E	Price/book
2014	-	-	-
2015	-	-	-
2016	-	-	-
2017	-	-	-
2018	-	-	-
2019	-	-	-
2020	-	-	-
2021	-	-	-
2022	-	-	-
2023	27.53	27.53	5.73

Business Segments (Million)

Compared With The

Period	Pharmaceutical products	Consumer Health Products
Q1 2021	107.12	14.70
Q2 2021	174.82	18.23
Q1 2022	203.09	40.70
Q2 2022	207.60	30.70
Q3 2022	206.65	31.11
Q4 2022	180.05	16.79
Q1 2023	258.50	42.35
Q2 2023	256.14	42.26
Q3 2023	251.49	41.12
Q4 2023	189.49	18.36
Q1 2024	334.33	51.13
Q2 2024	299.43	46.30

Period	Pharmaceutical products	Consumer Health Products
2020	731.16	74.15
2021	663.46	72.22
2022	797.38	119.30
2023	956.73	144.09

Analysts Estimates (Million)

Item	Q2 2024 (e)	Q2 2024 (a)	Change‬
Average	106.61	106.95	0.32 %

Estimates vs Actual (Million)

Item	Q2 2024 (e)	Q2 2024 (a)	Change
OSOOL AND BAKHEET	109.44	106.95	(2.3) %
Al Rajhi Capital	104.00	106.95	2.8 %
GIB Capital	116.00	106.95	(7.8) %
United Securities Company	97.00	106.95	10.3 %

Financial Ratios

	Current
Market Cap (M Riyal)	10,962.00
Enterprise Value (EV) (M)	10,840.18
Shares Outstanding ((M))	70.00
EPS ( Riyal) (TTM)	4.99
Book Value (BV) ( Riyal)	20.64
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	31.37
P/E (TTM)	31.37
Price/book	7.59
Return on Average Assets (%) (TTM)	19.9
Return on Average Equity (%) (TTM)	24.9

Jamjoom Pharmaceuticals Factory Co. (JAMJOOM PHARMA)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Jamjoom Pharma H1 2024 net profit rises to SAR 209.9M; Q2 at SAR 106.7M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2024 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Jamjoom Pharmaceuticals Factory Co. (JAMJOOM PHARMA)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Jamjoom Pharma H1 2024 net profit rises to SAR 209.9M; Q2 at SAR 106.7M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q2 2024

Revenue by Business Segment (Latest) 2024 Q2

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Jamjoom Pharmaceuticals Factory Co. (JAMJOOM PHARMA)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)